H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics today and set a price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen has given his Buy rating due to a combination of factors, primarily focusing on Barinthus Biotherapeutics’ promising developments in their clinical trials and strategic corporate actions. The company’s recent financial results showed a net loss that was less than anticipated, indicating better-than-expected financial management. Furthermore, the ongoing Phase 1 AVALON trial for VTP-1000, aimed at treating celiac disease, has shown no treatment-related serious adverse events, which is a positive indicator for the drug’s safety profile.
Additionally, the anticipated merger with Clywedog Therapeutics is expected to enhance Barinthus’s portfolio with assets targeting metabolic and autoimmune diseases, potentially increasing the company’s market value. The merger is projected to close in the first half of 2026, and the combined entity will have a broader pipeline with promising drugs like CLY-101 and CLY-201, which are in various stages of clinical trials. These strategic developments, coupled with the expected data releases from ongoing trials, underpin Yi Chen’s Buy rating and the adjusted price target of $4 per share.
Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, VolitionRX, and Oculis Holding. According to TipRanks, Chen has an average return of -6.9% and a 39.44% success rate on recommended stocks.